Lupus & antiphospholipid syndrome
Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways
Authors' conclusion
Belimumab treatment ameliorates multiple innate and adaptive immunity dysregulations of SLE and may reverse the disease signature, consistent with the drug effects on reducing activity and preventing flares. Fingerprints of innate immunity correlate with robust improvement whereas DNA damage response with less responsive disease to BAFF inhibition.
Study context
- Population
- Patients with active systemic lupus erythematosus (SLE) treated with belimumab
- Participants
- 45 paired samples
- Comparison
- Blood transcriptome at baseline vs after 6 months of belimumab; Lupus Low Disease Activity State (LLDAS)+ vs SRI-4+/LLDAS- response
- Outcome
- Transcriptome changes with belimumab
- Follow-up
- 6 months
Methodological detailslongitudinal, blood transcriptome (RNA-sequencing), weighted correlation network analysis (WGCNA), machine learning
- Longitudinal
- Blood transcriptome (RNA-sequencing)
- WGCNA
- Machine learning
Main finding
As reported in the abstract
50-gene set (incl. CCL4L2, CARD10, MMP15, KLRC2) predicted response to belimumab, cross-validated specificity (test set)
84%
Original publication
Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways. Ann Rheum Dis. Published 24 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →